Previous 10 | Next 10 |
home / stock / nvsef / nvsef news
2023-12-22 18:18:15 ET Summary Today, we revisit Bicycle Therapeutics plc, a UK-based clinical stage biotech company focused on developing medicines for underserved diseases. The company has inked two significant collaboration deals with large drug makers in 2023 and continues to ...
2023-12-19 13:13:17 ET Summary TG Therapeutics, Inc. stock has gone up a lot due to a Q3 revenue beat. However, look closely at the Q3 numbers, and you can see Briumvi wasn't responsible for the revenue beat. Briumvi hasn't done as well as it should have. My TG The...
2023-12-14 12:30:25 ET The Biden administration on Thursday named 48 Medicare Part B drugs that could be subject to inflation penalties for Q1 2024, including products from the likes of AbbVie ( NYSE: ABBV ), Amgen ( NASDAQ: AMGN ), and Pfizer ( NYSE: PFE ). Drug...
2023-12-11 13:57:54 ET More on MorphoSys MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis MorphoSys: Buying Constellation Was A Desperate Measure MorphoSys: Still Positive Moving Into Pelabresib Data (Maintaining Buy Rating) Mo...
2023-12-11 13:09:09 ET More on Keros Therapeutics Seeking Alpha’s Quant Rating on Keros Therapeutics Historical earnings data for Keros Therapeutics Financial information for Keros Therapeutics For further details see: Keros falls after mid-stage d...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...
2023-12-06 10:11:00 ET More on TG Therapeutics TG Therapeutics: Trying To Fill The Gap Back To $20 TG Therapeutics, Inc. (TGTX) Q3 2023 Earnings Call Transcript TG Therapeutics: Q3 Earnings Spike Hard To Explain Given Rival's Numbers TG Therapeutics gains aft...
Ad hoc announcement pursuant to Art. 53 LR Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients 1- 5 In APPLY-PNH, patients who sw...
2023-12-05 13:28:55 ET More on Olema Pharmaceuticals Olema Pharmaceuticals: Advancing On Multiple Fronts Olema: Two-Pronged Approach To Treat Breast Cancer Patients Olema Pharmaceuticals officer discloses sale of about 10K shares Seeking Alpha’s Quant ...
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...